TY - JOUR
T1 - Differential item functioning of the Arm function in Multiple Sclerosis Questionnaire (AMSQ) by language, a study in six countries
AU - Kalkers, Nynke F.
AU - Galan, Ingrid
AU - Kerbrat, Anne
AU - Tacchino, Andrea
AU - Kamm, Christian P.
AU - O’Connell, Karen
AU - McGuigan, Chris
AU - Edan, Gilles
AU - Montalban, Xavier
AU - Uitdehaag, Bernard M. J.
AU - Mokkink, Lidwine B.
N1 - Funding Information: The AMSQ is validated in six languages. All items have the same meaning to MS patients in Dutch, English, German, Spanish, French, and Italian. This validation study enables use of the AMSQ in international studies, for monitoring treatment response and disease progression. Multiple sclerosis arm function hand function upper extremity function questionnaire item response theory differential item functioning patient-reported outcome measure edited-state corrected-proof typesetter ts1 Declaration of Conflicting Interests The author(s) declared the following potential conflicts of interest with respect to the research, authorship, and/or publication of this article: N.F.K. received consultancy fees and speaking honoraria from Biogen Idec, Sanofi Genzyme, Novartis, Roche, and Teva. I.G. has nothing to disclose. A.K. has nothing to disclose. A.T. has nothing to disclose. C.P.K. has received honoraria for lectures as well as research support from Biogen, Novartis, Almirall, Bayer Schweiz AG, Teva, Merck, Sanofi Genzyme, Roche, Celgene, and the Swiss MS Society (SMSG). K.O. has received a travel and educational grant from Novartis to attend ECTRIMS 2017. C.M. has received research funding and/or honoraria from Actelion, Biogen, Merck, Novartis, Roche, Sandoz, and Sanofi Genzyme. G.E. has nothing to disclose. X.M. has received speaking honoraria and travel expenses for participation in scientific meetings, has been a steering committee member of clinical trials, or participated in advisory boards of clinical trials in the past years with Actelion, Bayer, Biogen, Celgene, Hoffmann-La Roche, Merck, Novartis, Oryzon Genomics, Sanofi Genzyme, and Teva Pharmaceutical. B.M.J.U. received consultancy fees from Biogen Idec, Genzyme, Merck Serono, Novartis, Roche, and Teva. L.B.M. has nothing to disclose. Funding The author(s) received no financial support for the research, authorship, and/or publication of this article. Publisher Copyright: © The Author(s), 2019. Copyright: Copyright 2021 Elsevier B.V., All rights reserved.
PY - 2021/1/1
Y1 - 2021/1/1
N2 - Background: The Arm function in Multiple Sclerosis Questionnaire (AMSQ) has been developed as a self-reported measure of arm and hand functioning for patients with multiple sclerosis (MS). The AMSQ was originally developed in Dutch and to date translated into five languages (i.e. English, German, Spanish, French, and Italian). Objective: The aim of this study was to evaluate differential item functioning (DIF) of the AMSQ in these languages. Methods: We performed DIF analyses, using “language” as the polytomous group variable. To detect DIF, logistic regression and item response theory principles were applied. Multiple logistic regression models were evaluated. We used a pseudo R2 value of 0.02 or more as the DIF threshold. Results: A total of 1733 male and female patients with all subtypes of MS were included. The DIF analysis for the whole dataset showed no uniform or non-uniform DIF on any of the 31 items. All R2 values were below 0.02. Conclusion: The AMSQ is validated in six languages. All items have the same meaning to MS patients in Dutch, English, German, Spanish, French, and Italian. This validation study enables use of the AMSQ in international studies, for monitoring treatment response and disease progression.
AB - Background: The Arm function in Multiple Sclerosis Questionnaire (AMSQ) has been developed as a self-reported measure of arm and hand functioning for patients with multiple sclerosis (MS). The AMSQ was originally developed in Dutch and to date translated into five languages (i.e. English, German, Spanish, French, and Italian). Objective: The aim of this study was to evaluate differential item functioning (DIF) of the AMSQ in these languages. Methods: We performed DIF analyses, using “language” as the polytomous group variable. To detect DIF, logistic regression and item response theory principles were applied. Multiple logistic regression models were evaluated. We used a pseudo R2 value of 0.02 or more as the DIF threshold. Results: A total of 1733 male and female patients with all subtypes of MS were included. The DIF analysis for the whole dataset showed no uniform or non-uniform DIF on any of the 31 items. All R2 values were below 0.02. Conclusion: The AMSQ is validated in six languages. All items have the same meaning to MS patients in Dutch, English, German, Spanish, French, and Italian. This validation study enables use of the AMSQ in international studies, for monitoring treatment response and disease progression.
KW - Multiple sclerosis
KW - arm function
KW - differential item functioning
KW - hand function
KW - item response theory
KW - patient-reported outcome measure
KW - questionnaire
KW - upper extremity function
UR - http://www.scopus.com/inward/record.url?scp=85077357430&partnerID=8YFLogxK
U2 - https://doi.org/10.1177/1352458519895450
DO - https://doi.org/10.1177/1352458519895450
M3 - Article
C2 - 31845614
SN - 1352-4585
VL - 27
SP - 90
EP - 96
JO - MULTIPLE SCLEROSIS JOURNAL
JF - MULTIPLE SCLEROSIS JOURNAL
IS - 1
ER -